Several well-known and widely debated radiopharmaceuticals for brain imaging include [18F]-FDG compounds used for imaging the alterations of glucose metabolism [188,189], [18F]-FDOPA tracers for dopamine synthesis in schizophrenia and PD, and other tracers for translocator proteins’ detection in AD and/or PD. This evidence concerns the gene TSPO and Parkinson disease.